Drug intelligence / Profile preview

DW4421S-T3

Development stage: Unknown
Lead developer: Daewon Pharm
Modality: Small Molecules
Administration: Oral

Overview

**DW4421S-T3** is a 30 mg oral tablet formulation of padoprazan, a small-molecule potassium-competitive acid blocker developed for gastroesophageal reflux disease. It competitively inhibits the potassium-binding site of the gastric hydrogen-potassium ATPase, producing rapid and potent suppression of gastric acid secretion. The formulation was evaluated as a once-daily, 7-day regimen in cohort 5 of a Phase 1 multiple-ascending-dose study in healthy adults. The broader padoprazan program is being advanced by Daewon Pharmaceutical in South Korea for erosive and non-erosive gastroesophageal reflux disease.

Targets

THRA (Thyroid hormone receptor alpha)TRα1-p43 (Thyroid hormone receptor alpha 1, mitochondrial (p43))αVβ3 (Integrin αVβ3)THRB (Thyroid hormone receptor beta)

Beyond the preview

Go deeper on DW4421S-T3.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DW4421S-T3.

Explore the full profile